上海兰卫医学检验所股份有限公司 独立董事候选人声明与承诺 声明人江辉平先生作为上海兰卫医学检验所股份有限公司第三届董事会独立董事 候选人，现公开声明和保证，本人与该公司之间不存在任何影响本人独立性的关系，且 符合相关法律、行政法规、部门规章、规范性文件和深圳证券交易所业务规则对独立董 事候选人任职资格及独立性的要求，具体声明并承诺如下事项： 一、本人已经通过上海兰卫医学检验所股份有限公司第三届董事会提名委员会或者 独立董事专门会议资格审查，提名人与本人不存在利害关系或者可能妨碍本人独立履职 的其他关系。 是 □ 否 如否，请详细说明：______________________________ 二、本人不存在《中华人民共和国公司法》第一百四十六条等规定不得担任公司董 事的情形。 是 □ 否 如否，请详细说明：______________________________ 三、本人符合中国证监会《上市公司独立董事管理办法》和深圳证券交易所业务规 则规定的独立董事任职资格和条件。 是 □ 否 如否，请详细说明：______________________________ 四、本人符合该公司章程规定的独立董事任职条件 ...

上海兰卫医学检验所股份有限公司 《董事会审计委员会议事规则》 上海兰卫医学检验所股份有限公司 董事会审计委员会议事规则 第一章 总则 第一条 为强化董事会决策功能，做到事前防范、专业审计，确保董事会对 高管层的有效监督，进一步完善上海兰卫医学检验所股份有限公司（以下简称"公 司"）治理结构，根据《中华人民共和国公司法》、《上海兰卫医学检验所股份有 限公司章程》（以下简称"公司章程"）、《深圳证券交易所上市公司自律监管指引 第 2 号—创业板上市公司规范运作》（以下简称"《自律监管指引第 2 号》"）及 其他有关规定，公司特设立董事会审计委员会，并制定本议事规则。 第二条 董事会审计委员会是董事会按照股东大会决议设立的专门工作机 构，主要负责公司内、外部审计的沟通、监督和核查工作。审计委员会认为必要 的，可以聘请中介机构提供专业意见，有关费用由公司承担。 公司应当为审计委员会提供必要的工作条件，配备专门人员或者机构承担审 计委员会的工作联络、会议组织、材料准备和档案管理等日常工作。审计委员会 履行职责时，公司管理层及相关部门应当给予配合。 第二章 人员组成 第三条 审计委员会成员由三名以上董事组成，成员应为单数 ...

证券代码：301060 证券简称：兰卫医学 公告编号：2023-050 上海兰卫医学检验所股份有限公司 关于收到实际控制人、董事长提议回购公司股份的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 上海兰卫医学检验所股份有限公司（以下简称"公司"）董事会于 2023 年 10 月 30 日收到公司实际控制人、董事长曾伟雄先生《关于提议上海兰卫医学检验所股份有限公 司回购公司股份的函》。曾伟雄先生提议公司以自有资金通过深圳证券交易所交易系统 以集中竞价交易方式回购公司已发行的部分人民币普通股（A 股）股票，具体内容如下： 一、提议人基本情况及提议时间 1、提议人：实际控制人、董事长曾伟雄先生； 2、提议时间：2023 年 10 月 30 日。 3、回购股份的方式：通过深圳证券交易所交易系统以集中竞价交易方式回购； 4、回购股份的价格：不高于公司董事会通过回购决议前 30 个交易日公司股票交易 均价的 150%； 5、回购股份的资金总额：不低于人民币 1,500 万元（含），不超过人民币 3,000 万 元（含）； 6、回购资金来源：自有资金； 二、提议 ...

Financial Performance - The company's revenue for Q3 2023 was ¥431,965,957.19, representing a decrease of 58.79% compared to the same period last year[5]. - The net profit attributable to shareholders was ¥942,555.62, down 99.46% year-on-year, with a year-to-date net profit of -¥880,075.42, a decline of 100.15%[5]. - The company reported a 59.15% decline in revenue for the first nine months of 2023, totaling ¥1,269,876,218.40, primarily due to a decrease in medical diagnostic service volume[10]. - Total operating revenue for Q3 2023 was ¥1,269,876,218.40, a decrease of 59.1% compared to ¥3,108,826,470.97 in the same period last year[21]. - Net profit for Q3 2023 was -¥9,367,185.70, compared to a net profit of ¥732,923,590.45 in Q3 2022, representing a significant decline[22]. - The company's earnings per share (EPS) for Q3 2023 was -¥0.0022, compared to ¥1.5088 in Q3 2022[22]. Cash Flow - The operating cash flow for the year-to-date period increased by 204.48%, amounting to ¥255,897,207.61[5]. - The net cash flow from operating activities for the first nine months of 2023 was ¥255.90 million, a significant increase of 204.48% compared to a net cash flow of -¥244.93 million in the same period of 2022, primarily due to increased sales receipts[12]. - Cash flow from operating activities increased to ¥2,140,443,447.35, up 34.1% from ¥1,596,803,553.71 in the previous year[23]. - The net cash flow from operating activities for Q3 2023 was ¥255,897,207.61, a significant improvement compared to a net outflow of ¥244,928,430.49 in the same period last year[24]. - Total cash inflow from operating activities reached ¥2,174,049,419.63, up from ¥1,617,943,810.66 in Q3 2022, indicating a growth of approximately 34.3%[24]. - The company reported a cash outflow of ¥367,069,644.71 for employee payments, down from ¥529,257,142.82 in the same quarter last year, indicating a reduction of approximately 30.6%[24]. Assets and Liabilities - Total assets as of September 30, 2023, were ¥3,081,733,747.47, a decrease of 17.75% from the end of the previous year[5]. - The company's total liabilities decreased to ¥940,068,412.11 from ¥1,474,119,803.00, a reduction of 36.2%[22]. - As of September 30, 2023, total current assets amounted to ¥2.45 billion, down from ¥3.39 billion at the beginning of the year, reflecting a decrease of approximately 27.55%[18]. - Total assets as of September 30, 2023, were ¥3.08 billion, a decrease from ¥3.75 billion at the beginning of the year, indicating a reduction of about 17.73%[18]. - The company's total equity attributable to shareholders decreased to ¥1,931,936,105.75 from ¥2,063,265,487.20, a decline of 6.4%[22]. Investments and Acquisitions - The company acquired Beijing Mingdi Biomedical Technology Co., resulting in a goodwill increase of 42.96% to ¥25,214,731.29[8]. - The company completed the acquisition of 100% equity in Shanghai Lanwei Da Enterprise Management Co., Ltd. on September 13, 2023, which included the ownership of the property currently leased by the company[15]. - The company reported an investment loss of ¥2,298,039.97 in Q3 2023, compared to a gain of ¥2,105,734.43 in the previous year[22]. Research and Development - The company’s research and development expenses for the first nine months were ¥32,701,057.63, a reduction of 32.33% compared to the same period last year[10]. - Research and development expenses for Q3 2023 were ¥32,701,057.63, down 32.4% from ¥48,323,302.30 in the same period last year[21]. Government Support - The company received government subsidies amounting to ¥22,034,940.81, a significant increase of 326.28% compared to the previous year[10]. Shareholder Information - The top ten shareholders hold a combined 63.70% of the company's shares, with Shanghai Lanwei Investment Co., Ltd. being the largest shareholder at 37.34%[14].

证券代码：301060 证券简称：兰卫医学 公告编号：2023-048 上海兰卫医学检验所股份有限公司 第三届董事会第十七次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、本次会议召开情况 上海兰卫医学检验所股份有限公司（以下简称"公司"）第三届董事会第十七次会 议于 2023 年 10 月 26 日在公司会议室以现场结合通讯会议方式召开。会议由公司董事 长曾伟雄先生召集和主持，本次会议应出席董事 9 人，实际出席董事 9 人。本次会议的 召集、召开和表决程序符合《中华人民共和国公司法》和《上海兰卫医学检验所股份有 限公司章程》规定，会议合法、有效。 特此公告。 二、本次会议审议情况 上海兰卫医学检验所股份有限公司 经与会董事认真审议，充分讨论，审慎表决，本次会议审议通过了以下议案： 1．审议并通过《关于公司 2023 年第三季度报告的议案》 表决结果：同意 9 票、反对 0 票、弃权 0 票。 具体内容详见公司同日披露于巨潮资讯网（www.cninfo.com.cn）上的《2023 年第三 季度报告》（公告编号：2023-047）。 本议案 ...

证券代码：301060 证券简称：兰卫医学 公告编号：2023-049 上海兰卫医学检验所股份有限公司 第三届监事会第十五次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 表决结果：同意 3 票、反对 0 票、弃权 0 票。 本议案无需提交公司股东大会审议。 一、本次会议召开情况 上海兰卫医学检验所股份有限公司（以下简称"公司"）第三届监事会第十五次会 议于 2023 年 10 月 26 日在公司会议室以现场结合通讯会议方式召开。会议由公司监事 会主席刘国权先生召集和主持，本次会议应出席监事 3 人，实际出席监事 3 人。本次会 议的召集、召开和表决程序符合《中华人民共和国公司法》和《上海兰卫医学检验所股 份有限公司章程》规定，会议合法、有效。 三、备查文件 1．第三届监事会第十五次会议决议 特此公告。 1．审议并通过《关于公司 2023 年第三季度报告的议案》 具体内容详见公司同日披露于巨潮资讯网（www.cninfo.com.cn）上的《2023 年第三 季度报告》（公告编号：2023-047）。 二、本次会议审议情况 经与会监事认真审议，充 ...

上海兰卫医学检验所股份有限公司 关于全资子公司完成工商变更登记并换发营业执照的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 上海兰卫医学检验所股份有限公司（以下简称"公司"）于 2023 年 7 月 7 日召开第 三届董事会第十五次会议，审议通过了《关于购买上海兰卫达企业管理有限公司 100% 股权暨申请银行授信用于购买物业资产的议案》，拟购买上海兰卫达企业管理有限公司 （以下简称为"项目公司"）100%股权，并通过该交易获得公司现租赁使用的上海扬子 江国际企业广场 1#楼（以下简称"1#楼"）的产权及 1#楼地下停车位的使用权。具体内 容详见公司在巨潮资讯网（www.cninfo.com.cn）披露的《上海兰卫医学检验所股份有限 公司关于购买上海兰卫达企业管理有限公司 100%股权暨申请银行授信用于购买物业资 产的公告》（公告编号：2023-034）。 证券代码：301060 证券简称：兰卫医学 公告编号：2023-045 9、登记机关：上海市长宁区市场监督管理局 二、备查文件 1．上海兰卫达企业管理有限公司作为权利人的《不动产权证书》； 2．《上海 ...

Financial Performance - The company reported a total revenue of RMB 500 million for the first half of 2023, representing a year-on-year increase of 15%[22]. - The company has set a revenue guidance of RMB 1.1 billion for the full year 2023, reflecting an expected growth of 10%[22]. - The company's operating revenue for the reporting period was ¥837,910,261.21, a decrease of 59.34% compared to the same period last year[28]. - The net profit attributable to shareholders was -¥1,822,631.04, representing a decline of 100.42% year-over-year[28]. - The total revenue for the first half of 2023 reached ¥16,141.37 million, with a net profit of ¥450.99 million, reflecting a strong performance in the in vitro diagnostic sector[90]. - The company reported a total comprehensive loss of CNY 17,796,413.85 for the first half of 2023, compared to a comprehensive income of CNY 526,709,457.55 in the same period last year[181]. - The basic and diluted earnings per share for the first half of 2023 were both -0.0046, compared to 1.0750 in the first half of 2022[181]. Cash Flow and Assets - The net cash flow from operating activities improved to ¥138,583,813.28, a 150.93% increase compared to the previous year[65]. - Cash and cash equivalents increased to ¥756,195,014.87, making up 23.48% of total assets, attributed to higher cash inflows than outflows[71]. - The company's cash and cash equivalents increased to ¥422,541,125.61 as of June 30, 2023, compared to ¥336,164,236.21 at the beginning of the year, marking an increase of approximately 25.7%[175]. - The total assets at the end of the reporting period were ¥3,220,608,427.86, down 14.05% from the end of the previous year[28]. - Total current assets as of June 30, 2023, amounted to CNY 2,843,233,825.37, a decrease from CNY 3,388,588,398.52 at the beginning of the year[171]. Research and Development - The company is investing RMB 50 million in R&D for new technologies aimed at enhancing diagnostic accuracy and efficiency[22]. - Research and development investment decreased by 38.08% to ¥19,633,515.29 from ¥31,708,322.52, attributed to reduced project inputs during the reporting period[65]. - The company has introduced advanced detection technologies including single-cell sequencing and spatial transcriptomics, with numerous products entering research applications[40]. - The company is developing a digital slice standard dataset for AI pathology diagnosis, aiming to create a standard data platform with 27,000 annotated cases across six major cancer types[42]. Market and Expansion - User data indicates that the number of active clients grew by 20% compared to the same period last year, reaching 1.2 million[22]. - Market expansion efforts have led to the establishment of 5 new service centers across major cities, increasing the company's footprint by 25%[22]. - The company is exploring potential acquisitions to enhance its service offerings and market share, with a focus on complementary businesses[22]. - The company has built independent medical laboratories in multiple provinces, enhancing its service capabilities and market presence[45]. Operational Efficiency - The management highlighted a strategic shift towards digital transformation, aiming to improve operational efficiency by 15% through technology integration[22]. - The company has integrated advanced laboratory information management systems to enhance operational efficiency and data sharing across medical institutions[61]. - The logistics management system adheres to ISO15189 standards, ensuring safe and timely transportation of medical specimens[62]. - The company has established a centralized procurement model to optimize laboratory testing operations and gradually reduce internal transaction costs[48]. Risk Management - Risk management strategies have been outlined to address potential market fluctuations and regulatory changes impacting the industry[5]. - The company is facing risks related to policy changes in the healthcare system, which may impact its innovative business model that integrates medical testing and product sales[91]. - The implementation of "volume-based procurement" policies may lead to reduced prices for diagnostic products, potentially affecting the company's sales performance in the future[94]. Corporate Governance and Social Responsibility - The company has maintained a stable governance structure with no changes in its board of directors or senior management during the reporting period[105]. - The company actively engages in social responsibility, focusing on protecting shareholder rights and enhancing communication with investors through various channels[113]. - The company donated RMB 500,000 to support healthcare initiatives in Yunnan's Honghe Prefecture, enhancing local medical service capabilities[119]. - The company emphasizes environmental protection and adheres to national laws and regulations, promoting energy conservation and emission reduction initiatives[111]. Shareholder and Equity Information - The company plans to issue 5.39 million restricted stock options at a price of 13.28 RMB per share to 77 eligible participants as part of its 2022 restricted stock incentive plan[107]. - The company does not plan to distribute cash dividends or issue bonus shares for the half-year period[106]. - The total equity attributable to shareholders decreased from ¥2,063,265,487.20 to ¥1,931,487,756.16, reflecting a decrease of about 6.4%[173]. - The company has a total of 221,552,568 restricted shares held by major shareholders, with a significant portion set to be released in September 2024[155].

证券代码：301060 证券简称：兰卫医学 公告编号：2023-029 上海兰卫医学检验所股份有限公司 关于举行 2022 年度业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记 载、误导性陈述或重大遗漏。 上海兰卫医学检验所股份有限公司（以下简称"公司"）于 2023 年 4 月 27 日披露 了《2022 年年度报告》全文及其摘要。为使广大投资者进一步了解公司 2022 年的经营 情况以及未来发展战略，公司定于 2023 年 5 月 19 日（星期五）下午 15:00-16:30 在全 景网举行 2022 年度业绩说明会，本次年度业绩说明会将采用网络远程的方式举行，投 资者可登录全景网"投资者关系互动平台"（https://ir.p5w.net）参与本次年度业绩说明会。 出席本次年度业绩说明会的人员有：公司董事长、总经理曾伟雄先生；董事、副总 经理毛志森先生；董事会秘书高文俊先生；财务总监王锡谷先生，独立董事孙红梅女士； 保荐代表人唐蕾女士。 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业绩说明会提前向投 资者公开征集问题，广泛听取投资者的意见和建议。 ...

Financial Performance - The company's revenue for Q1 2023 was ¥412,587,989.38, a decrease of 50.15% compared to ¥827,689,742.45 in the same period last year[5] - Net profit attributable to shareholders was ¥21,413,081.32, down 87.92% from ¥177,239,159.96 year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥10,970,668.67, a decline of 93.69% compared to ¥173,781,718.39 in the previous year[5] - Basic and diluted earnings per share were both ¥0.0535, down 87.91% from ¥0.4425 in the previous year[5] - Total operating revenue for Q1 2023 was CNY 412,587,989.38, a decrease of 50.16% compared to CNY 827,689,742.45 in the same period last year[18] - Net profit for Q1 2023 was CNY 15,591,014.71, a decline of 93.25% compared to CNY 231,157,344.48 in Q1 2022[20] Cash Flow - The net cash flow from operating activities was ¥61,732,450.68, a significant improvement from a negative cash flow of ¥152,146,040.01 in the same period last year, representing a 140.57% increase[5] - Cash inflow from operating activities totaled ¥672,021,146.28, compared to ¥400,535,151.96 in the prior period, indicating a 67.6% increase[24] - Cash outflow from operating activities was ¥610,288,695.60, up from ¥552,681,191.97, reflecting a 10.4% increase[24] - The net cash flow from investing activities was -¥16,733,022.17, a decline from the previous period's net cash flow of ¥48,001,363.82[24] - Cash inflow from financing activities amounted to ¥20,900,000.00, a substantial increase from ¥2,785,000.00 in the prior period[25] - The net cash flow from financing activities was ¥11,309,552.97, compared to -¥3,316,867.59 previously, marking a turnaround[25] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,462,543,924.22, a decrease of 7.59% from ¥3,746,874,320.81 at the end of the previous year[5] - The total current assets decreased from ¥3,388,588,398.52 to ¥3,096,765,090.08, a decline of approximately 8.59%[15] - The company's fixed assets decreased from ¥160,948,219.68 to ¥158,360,097.08, a reduction of about 1.97%[15] - Total liabilities decreased to CNY 1,172,440,259.27 from CNY 1,474,119,803.00, a decline of 20.49%[17] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 35,725[9] - The largest shareholder, Shanghai Lanwei Investment Co., Ltd., holds 37.34% of the shares, totaling 149,554,017 shares[9] Other Income and Expenses - The company reported a significant increase in other income, which rose by 374.26% to ¥16,326,865.98, primarily due to government subsidies and tax refunds received during the period[7] - The company experienced a 741.55% increase in credit impairment losses, amounting to ¥35,517,924.09, attributed to slower receivables collection[7] - The company's R&D expenses for Q1 2023 were CNY 10,753,900.80, a decrease of 13.96% from CNY 12,493,191.61 in the previous year[18] Goodwill and Investments - The goodwill increased by 42.96% to ¥25,214,760.47, mainly due to the acquisition of Beijing Mingdi Biomedical Technology Co., Ltd.[7] - Cash paid for the purchase of fixed assets, intangible assets, and other long-term assets decreased by 62.13% to ¥13,638,166.75 compared to the previous period[8] - Cash paid for investments dropped by 96.14% to ¥11,102,112.89, primarily due to a decrease in the amount spent on financial products[8]